Windtree Therapeutics Appoints New Chief Medical Officer
Ticker: WINTW · Form: 8-K · Filed: Aug 14, 2024 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Aug 14, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
TL;DR
Windtree Therapeutics just hired a new CMO, Dr. Paul J. Hastings. Big move for their drug pipeline.
AI Summary
Windtree Therapeutics, Inc. announced on August 13, 2024, the appointment of Dr. Paul J. Hastings as Chief Medical Officer. Dr. Hastings brings extensive experience in clinical development and regulatory affairs within the biotechnology sector. This appointment is part of the company's ongoing efforts to advance its pipeline of novel therapies.
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the strategic direction and execution of Windtree's drug development programs.
Risk Assessment
Risk Level: medium — The appointment of a new executive, especially a CMO, carries inherent risks related to integration, strategic alignment, and the future success of the company's clinical programs.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Dr. Paul J. Hastings (person) — Appointed Chief Medical Officer
- August 13, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Windtree Therapeutics?
Dr. Paul J. Hastings has been appointed as the new Chief Medical Officer.
What is the effective date of the earliest event reported in this 8-K filing?
The earliest event reported is dated August 13, 2024.
What is the primary business of Windtree Therapeutics?
Windtree Therapeutics is involved in the biological products sector, specifically focusing on therapies.
In which state was Windtree Therapeutics incorporated?
Windtree Therapeutics was incorporated in Delaware.
What is the Commission File Number for Windtree Therapeutics?
The Commission File Number for Windtree Therapeutics is 001-39290.
Filing Stats: 881 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2024-08-14 16:13:06
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share WINT The Nasdaq Capital Ma
Filing Documents
- wint20240812_8k.htm (8-K) — 24KB
- 0001437749-24-026816.txt ( ) — 154KB
- wint-20240813.xsd (EX-101.SCH) — 3KB
- wint-20240813_def.xml (EX-101.DEF) — 11KB
- wint-20240813_lab.xml (EX-101.LAB) — 15KB
- wint-20240813_pre.xml (EX-101.PRE) — 11KB
- wint20240812_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 13, 2024, the Board appointed Mark Strobeck, Ph.D., to serve as lead independent director, effective August 13, 2024, until his successor is duly qualified and elected or until his earlier death, resignation, or removal, or until otherwise determined by the Board.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 14, 2024 Windtree Therapeutics, Inc. By: /s/ Craig E. Fraser Name: Craig E. Fraser Title: President and Chief Executive Officer